drugset / Trial / NCT07028424
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment
Phase 2
Not yet recruiting
206 enrolled
GERCOR - Multidisciplinary Oncology Cooperative Group
Servier · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The main objective of PANORAMIX phase II trial is to optimize first-lie (L1) NALIRIFOX treatment for pancreatic cancer through the implementation of 5-fluorouracil (5-FU) maintenance therapy. Additionally, it aims to investigate the role of antibiotics and microbiota in second-line (L2) treatment.
Timeline
- Start
- 2025-07
- Primary completion
- 2029-07
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ciprofloxacin | Small molecule | 500 mg | — |
| Subject | Leucovorin | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Intravenous |
| Subject | fluorouracil | Small molecule | 2400 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Irinotecan Sucrosofate | Other / unclassified | 50 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 60 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |